Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Letaxaban. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 known ✓ | P00742 | 20/20 | 1.00 |
| ▸ | F2 | P00734 | 2/20 | 1.00 |
| ▸ | F9 | P00740 | 1/20 | 1.00 |
| ▸ | PLAT | P00750 | 1/20 | 1.00 |
| ▸ | KLKB1 | P03952 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Letaxaban SCHEMBL29375199 | 1.00 | F10 (1.00) | F10F2F9PLATKLKB1 | |
| Letaxaban SCHEMBL2855505 | 1.00 | F10 (1.00) | F10F2F9PLATKLKB1 | |
| Letaxaban SCHEMBL766143 | 1.00 | F10 (1.00) | F10F2F9PLATKLKB1 | |
| SCHEMBL2862509 | 0.95 | F10 (1.00) | F10F2F9PLATKLKB1 | |
| SCHEMBL2854445 | 0.87 | F10 (1.00) | F10F2F9PLATKLKB1 | |
| SCHEMBL2854447 | 0.87 | F10 (1.00) | F10F2F9PLATKLKB1 | |
| SCHEMBL2858092 | 0.87 | F10 (1.00) | F10F2F9PLATKLKB1 | |
| SCHEMBL1156987 | 0.86 | F10 (1.00) | F10F2F9PLATKLKB1 | |
| SCHEMBL13303264 | 0.86 | F10 (0.77) | F10F2F9PLATKLKB1 | |
| SCHEMBL2862268 | 0.86 | F10 (1.00) | F10F2F9PLATKLKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7745623-B2 | 1'-{(2S)-3-[(6-chloronaphthalen-2-yl)sulfonyl]-2-hydroxypropanoyl}-1,4'-bipiperidin-2-one or salts, useful as a drug for treating thrombosis | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-06-29 | — | — | US | claimed |
| US-20240390467-A1 | PROHEMOSTATIC PROTEINS FOR THE TREATMENT OF BLEEDING | ACADEMISCH ZIEKENHUIS LEIDEN (NL) | 2024-11-28 | — | — | US | disclosed |
| US-12083170-B2 | Prohemostatic proteins for the treatment of bleeding | ACADEMISCH ZIEKENHUIS LEIDEN (NL) | 2024-09-10 | — | — | US | disclosed |
| US-20220288172-A1 | PROHEMOSTATIC PROTEINS FOR THE TREATMENT OF BLEEDING | ACADEMISCH ZIEKENHUIS LEIDEN (US) | 2022-09-15 | — | — | US | disclosed |
| US-11304995-B2 | Prohemostatic proteins for the treatment of bleeding | ACADEMISCH ZIEKENHUIS LEIDEN (NL) | 2022-04-19 | — | — | US | disclosed |
| EP-3848353-A1 | MEDICAMENTS FOR THE TREATMENT OF OPHTHALMIC DISEASES | Takeda Pharmaceutical Company Limited (JP) | 2021-07-14 | — | — | EP | disclosed |
| EP-3149163-B1 | PROHEMOSTATIC PROTEINS FOR THE TREATMENT OF BLEEDING | ACADEMISCH ZIEKENHUIS LEIDEN (NL) | 2020-06-03 | — | — | EP | disclosed |
| US-20200138917-A1 | PROHEMOSTATIC PROTEINS FOR THE TREATMENT OF BLEEDING | ACADEMISCH ZIEKENHUIS LEIDEN (NL) | 2020-05-07 | — | — | US | disclosed |
| EP-2208726-B1 | Cyclic amide derivatives, and their production and use as antithrombotic agents | TAKEDA PHARMACEUTICAL (JP) | 2014-08-20 | — | — | EP | disclosed |
| US-8697865-B2 | Cyclic amide derivative, and its production and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-04-15 | — | — | US | disclosed |
| US-20100160629-A1 | CYCLIC AMIDE DERIVATIVE, AND ITS PRODUCTION AND USE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-06-24 | — | — | US | disclosed |
| US-20080255362-A1 | 1'-{(2S)-3-[(6-chloronaphthalen-2-yl)sulfonyl]-2-hydroxypropanoyl}-1,4'-bipiperidin-2-one or salts, useful as a drug for treating thrombosis | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-10-16 | — | — | US | disclosed |
| US-20080255362-A1 | 1'-{(2S)-3-[(6-chloronaphthalen-2-yl)sulfonyl]-2-hydroxypropanoyl}-1,4'-bipiperidin-2-one or salts, useful as a drug for treating thrombosis | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-10-16 | — | — | US | disclosed |
| US-20080255362-A1 | 1'-{(2S)-3-[(6-chloronaphthalen-2-yl)sulfonyl]-2-hydroxypropanoyl}-1,4'-bipiperidin-2-one or salts, useful as a drug for treating thrombosis | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-10-16 | — | — | US | disclosed |
| US-20080255352-A1 | 1'-{(2S)-3-[(6-chloronaphthalen-2-yl)sulfonyl]-2-hydroxypropanoyl}-1,4'-bipiperidin-2-one or salts, useful as a drug for treating thrombosis | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-10-16 | — | — | US | disclosed |
| US-20080255352-A1 | 1'-{(2S)-3-[(6-chloronaphthalen-2-yl)sulfonyl]-2-hydroxypropanoyl}-1,4'-bipiperidin-2-one or salts, useful as a drug for treating thrombosis | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-10-16 | — | — | US | disclosed |
| US-20080255352-A1 | 1'-{(2S)-3-[(6-chloronaphthalen-2-yl)sulfonyl]-2-hydroxypropanoyl}-1,4'-bipiperidin-2-one or salts, useful as a drug for treating thrombosis | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-10-16 | — | — | US | disclosed |
| US-20070244118-A1 | 1'-{(2S)-3-[(6-chloronaphthalen-2-yl)sulfonyl]-2-hydroxypropanoyl}-1,4'-bipiperidin-2-one or salts, useful as a drug for treating thrombosis | TAKEDA PHARMACEUTICAL COMPANY (JP) | 2007-10-18 | — | — | US | disclosed |
| US-20070244118-A1 | 1'-{(2S)-3-[(6-chloronaphthalen-2-yl)sulfonyl]-2-hydroxypropanoyl}-1,4'-bipiperidin-2-one or salts, useful as a drug for treating thrombosis | TAKEDA PHARMACEUTICAL COMPANY (JP) | 2007-10-18 | — | — | US | disclosed |
| US-20070244118-A1 | 1'-{(2S)-3-[(6-chloronaphthalen-2-yl)sulfonyl]-2-hydroxypropanoyl}-1,4'-bipiperidin-2-one or salts, useful as a drug for treating thrombosis | TAKEDA PHARMACEUTICAL COMPANY (JP) | 2007-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255352-A1 | 1'-{(2S)-3-[(6-chloronaphthalen-2-yl)sulfonyl]-2-hydroxypropanoyl}-1,4'-bipiperidin-2-one or salts, useful as a drug for treating thrombosis | JAK2, CNR1, F2 | F10 224/4885F2 3/4885F9 304/4885 |
| US-20100160629-A1 | CYCLIC AMIDE DERIVATIVE, AND ITS PRODUCTION AND USE | CNR1, CNR2, ARG1 | F10 305/4885F2 7/4885F9 240/4885 |
| US-20070244118-A1 | 1'-{(2S)-3-[(6-chloronaphthalen-2-yl)sulfonyl]-2-hydroxypropanoyl}-1,4'-bipiperidin-2-one or salts, useful as a drug for treating thrombosis | JAK2, CNR1, CNR2 | F10 232/4885F2 4/4885F9 294/4885 |
| US-20080255362-A1 | 1'-{(2S)-3-[(6-chloronaphthalen-2-yl)sulfonyl]-2-hydroxypropanoyl}-1,4'-bipiperidin-2-one or salts, useful as a drug for treating thrombosis | JAK2, CNR1, F2 | F10 224/4885F2 3/4885F9 304/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.